All Information (Except Text) for S.3094 - PRICED Act114th Congress (2015-2016)
|Sponsor:||Sen. Brown, Sherrod [D-OH] (Introduced 06/23/2016)|
|Committees:||Senate - Health, Education, Labor, and Pensions|
|Latest Action:||Senate - 06/23/2016 Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (All Actions)|
This bill has the status Introduced
Here are the steps for Status of Legislation:
There is 1 version of this bill. View text
Click the check-box to add or remove the section, click the text link to scroll to that section.
Titles Actions Overview All Actions Cosponsors Committees Related Bills Subjects Latest Summary All Summaries
Short Titles - Senate
Short Titles as Introduced
Price Relief, Innovation, and Competition for Essential Drugs Act
Actions Overview (1)
|06/23/2016||Introduced in Senate|
06/23/2016 Introduced in Senate
All Actions (1)
|06/23/2016||Read twice and referred to the Committee on Health, Education, Labor, and Pensions.|
Action By: Senate
06/23/2016 Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
|Sen. McCain, John [R-AZ]*||06/23/2016|
|Committee / Subcommittee||Date||Activity||Related Documents|
|Senate Health, Education, Labor, and Pensions||06/23/2016||Referred to|
Subject — Policy Area:
One Policy Area term, which best describes an entire measure, is assigned to every public bill or resolution.
Latest Summary (1)
Introduced in Senate (06/23/2016)
Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act
This bill amends the Public Health Service Act to allow biosimilars to be marketed seven years after the reference brand name biological product is licensed. Currently, brand name biological products are provided a 12-year marketing exclusivity period.This shortened marketing exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.